Article
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Leukemia research - 1 Feb 2012
Guillem Vicent, Amat Paula, Cervantes Francisco, Alvarez-Larrán Alberto, Cervera Jose, Maffioli Margherita, Bellosillo Beatriz, Collado María, Marugán Isabel, Martínez-Ruiz Francisco, Hernández-Boluda Juan-Carlos
Abstract excerpt
The function of the natural modulators of BCR-ABL-induced signaling pathways could influence the results to imatinib treatment. We assessed the association between single nucleotide polymorphisms (SNPs) on genes of the phosphatase family and the suppressors of cytokine signaling and the response to imatinib in 105 patients newly diagnosed with chronic-phase CML. SNPs in SOCS1 (rs243327) and PTPN22 (rs2476601)...
Read the complete abstract on PubMed